On November 5, 2018 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) reported that it has been selected to present at the BIO-Europe 24th Annual International Partnering Conference (Press release, Actinium Pharmaceuticals, NOV 5, 2018, View Source [SID1234530708]). The presentation is in addition to the Company’s planned partnering activities at the conference. Sandesh Seth, Actinium’s Chairman and CEO will provide an overview of the Company’s Antibody Radiation Conjugate (ARC) programs including its Iomab-B program and preliminary data from its pivotal Phase 3 SIERRA trial that has been accepted for oral presentation at ASH (Free ASH Whitepaper), its Iomab-ACT program for targeted lymphodepletion prior to CAR-T, its best in class CD33 program and its Antibody Warhead Enabling (AWE) technology platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Venue: Bella Center Copenhagen
Date: Tuesday, November 6, 2018
Time: 9:00 AM CET
Room: B2 on level 0
Category: Oncology
About BIO-Europe
The 24th annual BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships. BIO-Europe is organized by EBD Group, the leading partnering firm for the global biotechnology industry, in alliance with the Biotechnology Industry Organization (BIO)